CNSP - CNS Pharmaceuticals, Inc.
1.125
0.025 2.222%
Share volume: 42,211
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$1.10
0.02
0.02%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-15-2024 | 08-14-2023 | 11-14-2023 | 11-14-2024 | 05-15-2024 | 08-14-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 4.927 M | 4.025 M | 4.534 M | 5.379 M | 3.545 M | 2.528 M | 5.629 M | |
| Selling general and admin | 1.359 M | 1.180 M | 1.123 M | 1.108 M | 1.114 M | 1.412 M | 1.384 M | |
| Research and development | 3.568 M | 2.846 M | 3.411 M | 4.272 M | 2.430 M | 1.117 M | 4.245 M | |
| Total expenses | 4.927 M | 4.025 M | 4.534 M | 5.379 M | 3.545 M | 2.528 M | 5.629 M | |
| -18.29% | 12.63% | 18.65% | -34.10% | -28.68% | 122.65% | |||
| Operating income | -4.927 M | -4.025 M | -4.534 M | -5.379 M | -3.545 M | -2.528 M | -5.629 M | |
| Ebit | -4.927 M | -4.018 M | -4.521 M | -5.379 M | -3.545 M | -2.526 M | -5.604 M | |
| Pretax income | -4.932 M | -4.021 M | -4.523 M | -5.375 M | -3.545 M | -2.531 M | -5.606 M | |
| -18.47% | 12.47% | 18.85% | -34.05% | -28.61% | 121.51% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -4.932 M | -4.021 M | -4.523 M | -5.375 M | -3.545 M | -2.531 M | -5.606 M | |
| 18.47% | -12.47% | -18.85% | 34.05% | 28.61% | -121.51% |
